Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Harmonization of delirium severity instruments: a comparison of the DRS-R-98, MDAS, and CAM-S using item response theory.

Gross AL, Tommet D, D'Aquila M, Schmitt E, Marcantonio ER, Helfand B, Inouye SK, Jones RN; BASIL Study Group.

BMC Med Res Methodol. 2018 Sep 10;18(1):92. doi: 10.1186/s12874-018-0552-4.

2.

The Association Between Tetrahydrocannabinol and Lower Urinary Tract Symptoms Utilizing the National Health and Nutrition Examination Survey.

Fantus RJ, Riedinger CB, Chang C, Helfand BT.

Urology. 2018 Aug 21. pii: S0090-4295(18)30881-1. doi: 10.1016/j.urology.2018.06.054. [Epub ahead of print]

PMID:
30142408
3.

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB.

Prostate. 2018 Jul 24. doi: 10.1002/pros.23697. [Epub ahead of print]

PMID:
30043417
4.

Symptom Based Clustering of Women in the LURN Observational Cohort Study.

Andreev VP, Liu G, Yang CC, Smith AR, Helmuth ME, Wiseman JB, Merion RM, Weinfurt KP, Cameron AP, Lai HH, Cella D, Gillespie BW, Helfand BT, Griffith JW, DeLancey JOL, Fraser MO, Clemens JQ, Kirkali Z; LURN Study Group.

J Urol. 2018 Jul 7. pii: S0022-5347(18)43479-9. doi: 10.1016/j.juro.2018.06.068. [Epub ahead of print]

PMID:
29990467
5.

Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

Helfand BT, Chen H, Fantus RJ, Conran CA, Brendler CB, Zheng SL, Walsh PC, Isaacs WB, Xu J.

Prostate. 2018 Jun 19. doi: 10.1002/pros.23664. [Epub ahead of print]

PMID:
29923209
6.

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Hutten Selkirk C, Davidson R, Longmuir M, Eccles DM, Gadea N, Brewer C, Barwell J, Salinas M, Greenhalgh L, Tischkowitz M, Henderson A, Evans DG, Buys SS; IMPACT Study Steering Committee; IMPACT Collaborators, Eeles RA, Aaronson NK.

BJU Int. 2018 May 26. doi: 10.1111/bju.14412. [Epub ahead of print]

PMID:
29802810
7.

Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis.

Na R, Wu Y, Jiang G, Yu H, Lin X, Wang M, Conran CA, Fantus RJ, Zhang N, Liu S, Helfand BT, Zheng SL, Isaacs WB, Ding Q, Shen Z, Xu J.

BJU Int. 2018 May 4. doi: 10.1111/bju.14370. [Epub ahead of print]

PMID:
29727914
8.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J.

Prostate. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9.

PMID:
29520813
9.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

10.

Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study.

Helfand BT, Smith AR, Lai HH, Yang CC, Gore JL, Erickson BA, Kreder KJ, Cameron AP, Weinfurt KP, Griffith JW, Lentz A, Talaty P, Andreev VP, Kirkali Z; LURN.

J Urol. 2018 Aug;200(2):397-404. doi: 10.1016/j.juro.2018.02.075. Epub 2018 Mar 1.

11.

The Relationship between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES.

Fantus RJ, Packiam VT, Wang CH, Erickson BA, Helfand BT.

J Urol. 2018 Jul;200(1):161-166. doi: 10.1016/j.juro.2018.01.083. Epub 2018 Mar 27.

PMID:
29408214
12.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

13.

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM.

Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21.

PMID:
29275833
14.

Editorial Comment.

Helfand B.

J Urol. 2018 Feb;199(2):542. doi: 10.1016/j.juro.2017.08.134. Epub 2017 Nov 13. No abstract available.

PMID:
29144962
15.

Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study.

Cameron AP, Lewicky-Gaupp C, Smith AR, Helfand BT, Gore JL, Clemens JQ, Yang CC, Siddiqui NY, Lai HH, Griffith JW, Andreev VP, Liu G, Weinfurt K, Amundsen CL, Bradley CS, Kusek JW, Kirkali Z; Symptoms of Lower Urinary Tract Dysfunction Research Network Study Group.

J Urol. 2018 Apr;199(4):1023-1031. doi: 10.1016/j.juro.2017.10.035. Epub 2017 Oct 28.

16.

Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study.

Griffith JW, Messersmith EE, Gillespie BW, Wiseman JB, Flynn KE, Kirkali Z, Kusek JW, Bavendam T, Cella D, Kreder KJ, Nero JJ, Corona ME, Bradley CS, Kenton KS, Helfand BT, Merion RM, Weinfurt KP; LURN Study Group.

J Urol. 2018 Feb;199(2):528-535. doi: 10.1016/j.juro.2017.07.067. Epub 2017 Jul 20.

PMID:
28734864
17.

Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.

Chen H, Na R, Packiam VT, Conran CA, Jiang D, Tao S, Yu H, Lin X, Meng W, Zheng SL, Brendler CB, Helfand BT, Xu J.

Prostate. 2017 Aug;77(11):1179-1186. doi: 10.1002/pros.23369. Epub 2017 Jul 2.

PMID:
28670847
18.

Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.

Na R, Ye D, Qi J, Liu F, Helfand BT, Brendler CB, Conran CA, Packiam V, Gong J, Wu Y, Zheng SL, Mo Z, Ding Q, Sun Y, Xu J.

Prostate. 2017 Aug;77(11):1221-1229. doi: 10.1002/pros.23382. Epub 2017 Jun 30.

PMID:
28664580
19.

A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J.

Prostate. 2017 Aug;77(11):1213-1220. doi: 10.1002/pros.23380. Epub 2017 Jun 28.

20.

A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Helfand BT, Conran CA, Xu J, Catalona WJ.

Curr Opin Urol. 2017 Sep;27(5):475-480. doi: 10.1097/MOU.0000000000000418. Review.

21.

Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.

Tallman JE, Pearce SM, Kuchta K, Helfand BT, Eggener SE.

J Urol. 2017 Nov;198(5):1027-1032. doi: 10.1016/j.juro.2017.05.070. Epub 2017 May 25.

PMID:
28551443
22.
23.

Editorial Comment.

Helfand BT.

J Urol. 2017 Mar;197(3 Pt 1):782. doi: 10.1016/j.juro.2016.09.153. Epub 2016 Dec 16. No abstract available.

PMID:
27992747
24.

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL Jr, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB.

Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.

25.

Translating risk into revenue: strategies for risk-adjusted markets.

Solomon B, Helfand B.

Healthc Financ Manage. 2016 Nov;70(11):64-70. No abstract available.

PMID:
29897216
26.

Editorial Comment.

Helfand BT.

J Urol. 2017 Feb;197(2):341. doi: 10.1016/j.juro.2016.08.131. Epub 2016 Oct 24. No abstract available.

PMID:
27789308
27.

Editorial Comment.

Helfand BT.

J Urol. 2016 Nov;196(5):1491. doi: 10.1016/j.juro.2016.06.096. Epub 2016 Aug 1. No abstract available.

PMID:
27490423
28.

Factors Affecting Quality of Life at Different Intervals After Treatment of Localized Prostate Cancer: Unique Influence of Treatment Decision Making Satisfaction, Personality and Sexual Functioning.

Victorson DE, Schuette S, Schalet BD, Kundu SD, Helfand BT, Novakovic K, Sufrin N, McGuire M, Brendler C.

J Urol. 2016 Nov;196(5):1422-1428. doi: 10.1016/j.juro.2016.05.099. Epub 2016 May 31.

PMID:
27259651
29.

Editorial Comment.

Helfand BT.

J Urol. 2017 Jan;197(1):208-209. doi: 10.1016/j.juro.2016.07.109. Epub 2016 Oct 15. No abstract available.

PMID:
27750056
30.

Urologists' Current Practices in Screening and Treating Men With a Family History of Prostate Cancer.

Rudichuk L, Vogel KJ, Wang CH, Helfand BT, Selkirk CG.

Urology. 2017 Jan;99:180-185. doi: 10.1016/j.urology.2016.07.032. Epub 2016 Sep 16.

PMID:
27645528
31.

Misclassification Errors in Unsupervised Classification Methods. Comparison Based on the Simulation of Targeted Proteomics Data.

Andreev VP, Gillespie BW, Helfand BT, Merion RM.

J Proteomics Bioinform. 2016;Suppl 14. pii: 005. Epub 2016 May 16.

32.

Bladder Pneumatosis From a Catastrophic Vascular Event.

Cooke IJ, Okorji LM, Matulewicz RS, Oberlin DT, Helfand BT.

Urol Case Rep. 2016 Aug 4;8:58-60. doi: 10.1016/j.eucr.2016.07.002. eCollection 2016 Sep.

33.

Clinical validity and utility of genetic risk scores in prostate cancer.

Helfand BT, Kearns J, Conran C, Xu J.

Asian J Androl. 2016 Jul-Aug;18(4):509-14. doi: 10.4103/1008-682X.182981. Review.

34.

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J.

Prostate. 2016 Sep;76(12):1120-9. doi: 10.1002/pros.23200. Epub 2016 May 16.

35.

Variation in Testosterone Levels and Health-related Quality of Life in Men Diagnosed With Prostate Cancer on Active Surveillance.

Cohen A, Lapin B, Wang CH, Helfand B, Victorson D, Novakovic K.

Urology. 2016 Aug;94:180-7. doi: 10.1016/j.urology.2016.03.056. Epub 2016 May 11.

PMID:
27179775
36.

Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.

Na R, Ye D, Qi J, Liu F, Lin X, Helfand BT, Brendler CB, Conran C, Gong J, Wu Y, Gao X, Chen Y, Zheng SL, Mo Z, Ding Q, Sun Y, Xu J.

Asian J Androl. 2016 Jul-Aug;18(4):525-9. doi: 10.4103/1008-682X.179857.

37.

A comparison of genetic risk score with family history for estimating prostate cancer risk.

Helfand BT.

Asian J Androl. 2016 Jul-Aug;18(4):515-9. doi: 10.4103/1008-682X.177122. Review.

38.

To PSA or not to PSA? Still a question for men with a family history of prostate cancer.

Selkirk CG, Helfand BT.

BJU Int. 2016 Apr;117(4):545. doi: 10.1111/bju.13372. No abstract available.

39.

Mutational Landscape of Aggressive Prostate Tumors in African American Men.

Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, Simko JP, Ngo V, Chen Y, Levin AM, Chitale D, Helfand BT, Catalona WJ, Rybicki BA, Witte JS.

Cancer Res. 2016 Apr 1;76(7):1860-8. doi: 10.1158/0008-5472.CAN-15-1787. Epub 2016 Feb 26.

40.

Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer.

Stacey SN, Kehr B, Gudmundsson J, Zink F, Jonasdottir A, Gudjonsson SA, Sigurdsson A, Halldorsson BV, Agnarsson BA, Benediktsdottir KR, Aben KK, Vermeulen SH, Cremers RG, Panadero A, Helfand BT, Cooper PR, Donovan JL, Hamdy FC, Jinga V, Okamoto I, Jonasson JG, Tryggvadottir L, Johannsdottir H, Kristinsdottir AM, Masson G, Magnusson OT, Iordache PD, Helgason A, Helgason H, Sulem P, Gudbjartsson DF, Kong A, Jonsson E, Barkardottir RB, Einarsson GV, Rafnar T, Thorsteinsdottir U, Mates IN, Neal DE, Catalona WJ, Mayordomo JI, Kiemeney LA, Thorleifsson G, Stefansson K.

Hum Mol Genet. 2016 Mar 1;25(5):1008-18. doi: 10.1093/hmg/ddv622. Epub 2016 Jan 5.

41.

A Longitudinal Study of Predictors of Sexual Dysfunction in Men on Active Surveillance for Prostate Cancer.

Pearce SM, Wang CH, Victorson DE, Helfand BT, Novakovic KR, Brendler CB, Albaugh JA.

Sex Med. 2015 Sep;3(3):156-64. doi: 10.1002/sm2.78. Epub 2015 Jul 30.

42.

Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.

Kearns JT, Lapin B, Wang E, Roehl KA, Cooper P, Catalona WJ, Helfand BT.

Eur Urol. 2016 Feb;69(2):223-8. doi: 10.1016/j.eururo.2015.09.004. Epub 2015 Sep 26.

43.

Analyzing Why Men Seek Treatment for Lower Urinary Tract Symptoms and Factors Associated With Nonimprovement.

Welliver C, Sulaver R, Whittington A, Helfand BT, Çakır ÖO, Griffith JW, McVary KT.

Urology. 2015 Nov;86(5):862-7. doi: 10.1016/j.urology.2015.08.006. Epub 2015 Aug 20.

PMID:
26299465
44.

Editorial Comment.

Helfand BT.

Urology. 2015 Sep;86(3):579-80. doi: 10.1016/j.urology.2015.04.058. Epub 2015 Jul 23. No abstract available.

PMID:
26210002
45.

Temporary erectile dysfunction after prostate biopsy.

Helfand BT.

BJU Int. 2015 Aug;116(2):164. doi: 10.1111/bju.13022. No abstract available.

46.

Comparison of Patients Undergoing PVP Versus TURP for LUTS/BPH.

Anderson BB, Pariser JJ, Helfand BT.

Curr Urol Rep. 2015 Aug;16(8):55. doi: 10.1007/s11934-015-0525-7. Review.

PMID:
26077354
47.

Characteristics of Men Undergoing Testosterone Replacement Therapy and Adherence to Follow-up Recommendations in Metropolitan Multicenter Health Care System.

Malik RD, Wang CE, Lapin B, Lakeman JC, Helfand BT.

Urology. 2015 Jun;85(6):1382-8. doi: 10.1016/j.urology.2015.01.027. Epub 2015 Apr 7.

PMID:
25862121
48.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

49.

Reply: To PMID 25709045.

Selkirk CG, Wang CH, Helfand BT.

Urology. 2015 Apr;85(4):746-7. doi: 10.1016/j.urology.2014.10.062. Epub 2015 Feb 21. No abstract available.

PMID:
25709048
50.

Family history of prostate cancer in men being followed by active surveillance does not increase risk of being diagnosed with high-grade disease.

Selkirk CG, Wang CH, Lapin B, Helfand BT.

Urology. 2015 Apr;85(4):742-7. doi: 10.1016/j.urology.2014.10.060. Epub 2015 Feb 21.

PMID:
25709045

Supplemental Content

Loading ...
Support Center